Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
First Claim
Patent Images
1. A method to treat osteolytic bone destruction resulting from myeloma in a subject comprising administering to a subject in need of such treatment an effective amount of PSI or PPM-18.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-κB. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-κB provides a useful means to identify agents to treat myeloma bone disease.
-
Citations
2 Claims
- 1. A method to treat osteolytic bone destruction resulting from myeloma in a subject comprising administering to a subject in need of such treatment an effective amount of PSI or PPM-18.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeOsteoscreen IP, LLC
-
Original AssigneeOsteoScreen, Inc.
-
InventorsMundy, Gregory R.
-
Primary Examiner(s)Criares, Theodore J.
-
Application NumberUS09/289,229Time in Patent Office1,341 DaysField of Search514/12, 514/18, 514/13, 514/613, 514/617US Class Current514/16.7CPC Class CodesA61K 31/165 having aromatic rings, e.g....A61K 31/166 having the carbon of a carb...A61K 31/40 having five-membered rings ...A61K 31/435 having six-membered rings w...A61K 31/66 Phosphorus compoundsA61K 38/05 DipeptidesA61K 38/06 TripeptidesA61P 19/08 for bone diseases, e.g. rac...A61P 35/00 Antineoplastic agentsA61P 43/00 Drugs for specific purposes...
